Factor 8 deficiency, known medically as hemophilia A, is a bleeding disorder in which your blood lacks enough of a protein called factor VIII, one of the key ingredients your body needs to form clots. Without adequate factor VIII, bleeding episodes last longer than normal and can occur internally without any obvious injury. It affects roughly 1 in every 5,617 male births in the United States, making it the most common type of hemophilia.
How Factor VIII Helps Your Blood Clot
When you cut yourself or damage a blood vessel, your body launches a chain reaction of proteins that work together to build a clot and stop the bleeding. Factor VIII is a critical link in that chain. It acts as a helper molecule, pairing with another clotting protein (activated factor IX) on a surface of calcium and fats to activate factor X. Factor X then triggers the production of fibrin, the mesh-like material that holds a clot together.
Without enough functioning factor VIII, that chain reaction stalls. The clot either forms too slowly or doesn’t form well enough to stop the bleeding. The severity depends on how much factor VIII activity remains in your blood: severe hemophilia A means less than 1% of normal activity, moderate means 1 to 5%, and mild means 6 to 40%.
Why It Mostly Affects Males
The gene that tells your body how to make factor VIII sits on the X chromosome. Males have one X and one Y chromosome, so a single faulty copy of the gene is enough to cause the condition. Females have two X chromosomes, meaning the working copy on the second X usually compensates for a faulty one on the first. This is why hemophilia A overwhelmingly appears in boys and men, while women typically carry the gene without symptoms.
A woman who carries one altered copy has a 50% chance of passing it to each child. Her sons who inherit the altered X will have hemophilia A. Her daughters who inherit it will usually be carriers, though some carriers do experience milder bleeding symptoms if the working X chromosome isn’t fully compensating.
In some cases, factor VIII deficiency isn’t inherited at all. A rare form called acquired hemophilia A occurs when the immune system mistakenly produces antibodies that attack factor VIII. This can appear in older adults, during pregnancy, or alongside autoimmune conditions, and it requires a different diagnostic workup.
Common Signs and Symptoms
The hallmark of factor VIII deficiency is bleeding that is prolonged, excessive, or happens in unusual locations. The specific symptoms depend heavily on severity. People with the severe form often bleed spontaneously, while those with mild deficiency may only notice problems after surgery, dental work, or a significant injury.
The most characteristic symptom is bleeding into the joints, particularly the knees, elbows, and ankles. These bleeds cause swelling, pain, and tightness, and over time repeated joint bleeds lead to chronic joint disease and lasting damage. Other common signs include:
- Easy bruising or large bruises from minor bumps
- Prolonged bleeding from cuts, tooth loss, or dental procedures
- Nosebleeds that are frequent and hard to stop
- Bleeding after vaccinations or routine injections
- Blood in urine or stool
- Muscle and soft tissue bleeding that creates pockets of pooled blood (hematomas)
In newborns, the first sign is sometimes excessive bleeding after circumcision or bleeding in the head following a difficult delivery. Many boys with severe hemophilia A are diagnosed within the first year of life, while milder cases may go undetected until adolescence or adulthood.
How Factor VIII Deficiency Is Diagnosed
If your doctor suspects a bleeding disorder, the first screening test is usually a blood test called the activated partial thromboplastin time, or aPTT. This measures how long it takes for part of the clotting chain to work. In factor VIII deficiency, the aPTT is prolonged because the chain reaction that factor VIII participates in is impaired.
A prolonged aPTT alone doesn’t confirm the diagnosis, though. Several other conditions can cause the same result. The definitive test is a factor VIII activity assay, which directly measures how much functional factor VIII is in your blood. The result determines both the diagnosis and the severity classification. Additional testing may be done to rule out von Willebrand disease, a more common bleeding disorder that can also lower factor VIII levels indirectly.
Treatment With Factor Replacement
The primary treatment for factor VIII deficiency is replacing the missing protein through intravenous infusion. These replacement products come in two forms: concentrates made from donated human plasma, and recombinant products manufactured in a lab without human blood. Both work by restoring factor VIII levels enough for the blood to clot normally.
Treatment follows two strategies. On-demand treatment means infusing factor VIII in response to an active bleeding episode to stop it. Prophylactic treatment means infusing factor VIII on a regular schedule, typically two to three times per week, to prevent bleeds from happening in the first place. Prophylaxis is the standard approach for people with severe hemophilia A, especially children, because it protects joints from the cumulative damage of repeated bleeds.
Both plasma-derived and recombinant products are effective, though they differ in important ways. Plasma-derived products contain additional proteins, including von Willebrand factor, which naturally stabilizes factor VIII in the bloodstream. Recombinant products are free of these companion proteins. Both undergo safety processing to eliminate viruses, and both carry some risk of triggering an immune response (more on that below).
Non-Factor Therapies
A newer treatment option has significantly changed daily life for many people with hemophilia A. Emicizumab is an engineered antibody that mimics what factor VIII does. It physically bridges the same two proteins (activated factor IX and factor X) that factor VIII normally brings together, allowing the clotting chain to proceed even without factor VIII present.
The practical advantage is major: emicizumab is given as a subcutaneous injection, meaning a shot under the skin rather than into a vein. It’s administered once a week or less frequently, compared to the multiple weekly IV infusions that traditional factor replacement requires. This has been especially transformative for young children and for people who have developed immune resistance to standard factor VIII products.
The Inhibitor Problem
One of the most significant complications of factor VIII deficiency is the development of inhibitors. These are antibodies your immune system creates that recognize infused factor VIII as foreign and neutralize it before it can work. Up to 33% of people with hemophilia A develop inhibitors, most commonly within the first 50 days of treatment exposure.
Inhibitors make standard replacement therapy less effective or completely ineffective. People with low levels of inhibitors may still respond to higher doses of factor VIII. Those with high levels need alternative approaches that bypass factor VIII entirely in the clotting chain, using different activated clotting proteins to achieve hemostasis through a parallel route.
The long-term goal for someone with inhibitors is to eliminate them through a process called immune tolerance induction. This involves giving frequent, regular doses of factor VIII over months or even years to train the immune system to stop reacting against it. Success rates vary, but eradicating the inhibitor allows patients to return to standard factor replacement, which is generally more effective and predictable for preventing bleeds.
Living With Factor VIII Deficiency
With modern treatment, most people with hemophilia A can expect a near-normal lifespan. The key is consistent prophylaxis to prevent joint damage, which remains the most common long-term complication. Joints that have already been damaged by repeated bleeds develop a form of arthritis that causes chronic pain and limits mobility, so early and consistent prevention matters enormously.
Physical activity is encouraged rather than restricted for most people with hemophilia A, though contact sports and activities with high injury risk require careful consideration and planning. Many treatment centers recommend working with a physiotherapist to build joint-supporting muscle strength. People with the condition typically carry identification and a treatment plan so that emergency responders or unfamiliar hospitals can manage bleeding quickly if needed.